COVID-19: Potential Repurposing Drugs
Issued Date
2022-02-01
Resource Type
ISSN
18715265
eISSN
18755852
Scopus ID
2-s2.0-85128274070
Pubmed ID
33645490
Journal Title
Infectious Disorders - Drug Targets
Volume
22
Issue
1
Start Page
50
End Page
61
Rights Holder(s)
SCOPUS
Bibliographic Citation
Infectious Disorders - Drug Targets Vol.22 No.1 (2022) , 50-61
Suggested Citation
Leowattana W. COVID-19: Potential Repurposing Drugs. Infectious Disorders - Drug Targets Vol.22 No.1 (2022) , 50-61. 61. doi:10.2174/1871526521666210301143441 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/86124
Title
COVID-19: Potential Repurposing Drugs
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the most infectious diseases which has been caused by coronavirus in 2019 (COVID-19). It has widely spread worldwide and infected more than 28 million people in 215 countries, and more than 920,000 have now died from COVID-19. To date, no effective antiviral drugs or specific vaccines have been discovered yet. Considering this situation, the potential therapeutic antiviral drug targets for the COVID-19 are being repurposed to speed up the discovery of effective treatment. The most potential drug targets that are continuously being recommended include Favipiravir, Chloroquine, Hydroxychloroquine, and Remdesivir. Moreover, the antiviral target proteins and anti-host target proteins are being reported continuously. This review has summarized the current research studies on potential therapeutic drug targets that are being tested against the SARS-CoV-2. It will provide information related to potential repurposing drugs for overcoming COVID-19.